Hypomethylating agents after allogeneic blood stem cell transplantation

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Allogeneic blood stem cell transplantation (allo-SCT) offers curative potential for myeloid malignancies but relapse is a significant cause of treatment failure.
• Current salvage options for post-allo-SCT relapse in AML and MDS are limited, with dismal prognoses.
• Novel therapeutic strategies are urgently needed to improve outcomes for patients relapsing after allo-SCT.

Approach:

• This review examines the use of hypomethylating agents (HMA), azacitidine (Aza) and decitabine (DAC), in the post-transplant setting for myeloid malignancies.
• It synthesizes data from retrospective and prospective studies on HMA as pre-emptive, salvage, or consolidation therapy.
• The review also discusses practical aspects like dosing, scheduling, patient selection, and the role of cellular interventions.

Key Points:

• HMA (azacitidine and decitabine) have demonstrated a balanced efficacy and toxicity profile in non-transplant settings.
• These agents are being investigated alone or in combination with donor lymphocyte infusions (DLI) after allo-SCT.
• The review covers current knowledge, practical considerations, and ongoing research for HMA in the post-transplant setting.

Conclusions:

• HMA represent a promising therapeutic avenue for managing relapse after allo-SCT in AML and MDS.
• Optimizing HMA use, including dose, schedule, and combinations with cellular therapies, is crucial for improving outcomes.
• Further clinical studies are essential to establish the definitive role of HMA in this patient population.